Osmofundina Concentrada (Mannitol)

Mannitol is an osmotically active sugar alcohol that, when given intravenously, raises plasma osmolality. The resulting gradient draws water from cells and interstitial spaces into the bloodstream, decreasing tissue swelling, lowering pressure in the brain and eye, and increasing urine output through enhanced glomerular filtration.

The dose of Osmofundina Concentrada is determined by the prescribing clinician based on the specific indication, patient weight, renal function and clinical response. Healthcare professionals adjust the infusion rate and total amount to achieve the desired osmotic effect while monitoring safety parameters.

Limited clinical data exist for mannitol use during pregnancy and lactation. It is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mannitol is a widely used osmotic diuretic with a rapid onset and predictable plasma‑osmolality increase. Compared with hypertonic saline, mannitol provides a larger osmotic gradient without adding sodium load, making it preferable for patients where sodium restriction is important. Choice of agent depends on clinical context and physician judgment.

Store Osmofundina Concentrada at ambient temperature, preferably below 25 °C. Keep the container sealed, protect it from moisture and direct sunlight, and avoid freezing. Follow any additional handling instructions on the label to maintain product integrity until use.

The product is supplied as a sterile concentrated solution for intravenous infusion. It is diluted in an appropriate compatible fluid and administered by a healthcare professional under controlled infusion rates, usually over a period of minutes to hours, depending on the therapeutic goal and patient tolerance.

Serious adverse events include pulmonary edema, severe hyponatremia, anaphylactic reactions and worsening renal failure. These conditions require immediate medical attention and may be life‑threatening. Patients should be closely monitored for signs of fluid overload, electrolyte disturbances and allergic responses during and after infusion.

Contraindications include patients with anuria, severe renal impairment, uncontrolled dehydration, known hypersensitivity to mannitol, and those with active intracranial hemorrhage where increased intracranial volume could be harmful. Clinicians must assess each patient’s medical history before initiating therapy.